However, the absolute difference in mOS in months was not so clear between the different prognostic groups of the Lung-molGPA and DS-GPA scoring systems, something which could question the need for four prognostic groups for ALK+ NSCLC patients with BM, instead of two, as in the ALK-BPI. This evidence concerns the gene ALK and non-small cell lung carcinoma.